Apothecary Pharma recalls 22 tirzepatide vials and one NAD+ vial nationwide
The FDA classified the voluntary recall Class II on Oct. 8, roughly ten months after warning the North Carolina compounder over sterile production practices.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 20 16:57 ETSource: Fox Business
The wire
- 01The recall covers 18 mg/mL compounded tirzepatide in 4 mL multidose vials, lots AP-202622 through AP-202625 and AP-202627 through AP-202644, plus one 200 mg/mL NAD+ vial, lot AP-202647, all for lack of sterility assurance.
- 02Pharmacists and telehealth prescribers sourcing from outsourcing facilities should check vials and records; the FDA cited serious deficiencies in the firm's sterile production in a December 2025 warning letter, though it has not linked those findings to this recall.
- 03No illnesses or injuries have been reported; the recall, begun Sept. 24, remains ongoing, and patients with fever, redness, swelling or worsening pain after injection are told to seek medical advice.
From the source
Read at foxbusiness.comGLP-1 injections recalled nationwide over sterility concerns
FOX Business correspondent Grady Trimble reports on how GLP-1 weight loss drugs are fueling a massive demand for whey protein on 'The Claman Countdown.'
